Russian Federation
Russian Federation
Patients with type 2 diabetes mellitus (DM) have a high risk of secondary cardiorenal syndrome, which increases the death rate in these patients. Diabetes-associated heart and kidney damage is an important and largely underestimated cause of global morbidity and mortality. The research for new combinations of cardionephroprotective drugs is currently an urgent task. The aim of this study was to evaluate the effectiveness of the combination of valsartan and amlodipine versus the combination of sacubitril/valsartan and amlodipine in relation to cardiac and nephroprotection in patients with type 2 diabetes mellitus. The study involved 96 patients with type 2 diabetes with secondary cardiorenal syndrome. There were 54 (56.25%) men and 42 (43.75%) women. The average age was 60.27±7.53 years. During the study, patients were randomized into two groups. Group 1 (n=48) consisted of patients with type 2 diabetes with age 59.38±7.74 years who received a combination of valsartan and amlodipine for 6 months. Group 2 (n=48) consisted of patients with type 2 diabetes with age 61.17±7.29 years who received therapy which consisted of sacubitrile/valsartan and amlodipine for the same time. The control group consisted of 40 practically healthy volunteers whose average age was 60.3 ± 7.0 years. It was revealed that cardiac markers NT-proBNP, cystatin C, aldosterone are integral indicators of the risk of developing cardiovascular and renal dysfunctions, and increases in patients with type 2 diabetes indicates a high probability of progression of secondary cardiorenal syndrome. A six-month therapy with a combination of antihypertensive drugs valsartan with amlodipine and sacubitrile/valsartan with amlodipine in patients with type 2 diabetes equally effectively reduces blood pressure, while NT-proBNP and cystatin C significantly decrease against the background of an increase in glomerular filtration rate. In patients with secondary cardiorenal syndrome who received a combination of sacubitril/valsartan and amlodipine there was a more pronounced dynamics of a decrease in albuminuria and aldosterone levels.
diabetes mellitus, cardiovascular complications, kidneys, treatment
1. Barbuk O. A. Kardiorenal'nyy sindrom: osnovnye problemy diagnostiki i lecheniya. Medicinskie novosti. 2018;3:60-65.
2. Davydov V. V., Arehina E. L. Rol' cistatina s v ranney diagnostike progressirovaniya hronicheskoy bolezni pochek u pacientov s ostroy dekompensaciey hronicheskoy serdechnoy nedostatochnosti. Consillium Medicum. 2018;20(12):30-34. doihttps://doi.org/10.26442/20751753.2018.12.180155.
3. Kukes V. G., Prokof'ev A. B., Zhestovskaya A. S., Smirnov V.V. Povyshenie sekrecii al'dosterona u bol'nyh s hronicheskoy serdechnoy nedostatochnost'yu i puti ee normalizacii. Klinicheskaya farmakologiya i terapiya. 2016;25(3):64-66.
4. Medvedeva E. A., Shilyaeva N. V., Ishakov E. N., Schukin Yu. V. Kardiorenal'nyy sindrom pri hronicheskoy serdechnoy nedostatochnosti: patogenez, diagnostika, prognoz i vozmozhnostiterapii. Rossiyskiy kardiologicheskiy zhurnal. 2017;141(1):136-141. doihttps://doi.org/10.15829/1560-4071-2017- 1-136-141.
5. Skvorcov V. V., Molchanova I. V. Mesto i rol' antagonistov al'dosterona v lechenii arterial'noy gipertenzii. Terapevt. 2019;7:55-61.
6. Taglieri N., Kenig V., Kaski K. Cistatin S i risk serdechno-sosudistyh zabolevaniy. Laboratornaya medicina za rubezhom. 2012;55(11):1932- 1943.
7. Shevelek A. N. Vzaimosvyaz' plazmennyh urovney al'dosterona i pokazateley uglevodnogo obmena pri hronicheskoy serdechnoy nedostatochnosti s sohranennoy frakciey vybrosa. Rossiy- skiy kardiologicheskiy zhurnal. 2021;26(1):10-16. doihttps://doi.org/10.15829/1560-4071-2021-3991.
8. Beltran P., Palau P., Domnnguez E. Sacubitril/ valsartan and short-term changes in the 6-minute walk test: A pilot study. International Journal of Cardiology. 2018;252:136-139. doihttps://doi.org/10.1016/j.ijcard.2017.10.074.
9. Bohm M., Young R., Jhund P. S. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal. 2017;38(15):1132-1143. doi: https://doi.org/10.1093/eurheartj/ ehw570.
10. Campion C. G., Sanchez-Ferras O., Batchu S. N. Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy. Can. J. Kidney Health Dis. 2017;4:435-537. doihttps://doi.org/10.1177/2054358117705371.
11. Nishikimi T., Inaba-Iemura C., Ishimura K. Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pept. 2009;154(1-3):44-53. doi:https://doi.org/10.1016/j.regpep.2009.02.006
12. Seferovic P. M., Petrie M. C., Filippatos G. S. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853-872. doi:https://doi.org/10.1002/ejhf.1170.
13. Tucker P. S., Scanlan A. T., Dalbo V. J. Chronic kidney disease influences multiple systems: describing the relationship between oxidative stress, inflammation, kidney damage, and concomitant disease. Oxid. Med. Cell. Longev. 2015;2015:853-58. doihttps://doi.org/10.1155/2015/806358.
